<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02668692</url>
  </required_header>
  <id_info>
    <org_study_id>LP0076-1128</org_study_id>
    <nct_id>NCT02668692</nct_id>
  </id_info>
  <brief_title>LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis</brief_title>
  <official_title>Efficacy and Safety of LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CMIC Co, Ltd. Japan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of LEO 80185 gel with Dovobet® ointment in the treatment
      of psoriasis in Japanese subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 3, national, multi-centre, 4-week, prospective, randomised, controlled,
      parallel-group, open trial of LEO 80185 gel versus Dovobet® ointment in Japanese subjects
      with psoriasis vulgaris.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>'overall improvement' for the target lesion on the scalp, defined as 'substantial resolution' of clinical signs and/or at least 'moderately improved' in the general change in the lesion</measure>
    <time_frame>end of week 4</time_frame>
    <description>'Substantial resolution' is defined as a clinical score for thickness and scaliness of 0 and a clinical score for redness of 1 or less in the severity of clinical signs of the lesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>'overall improvement' for the target lesion on the non-scalp area, defined as 'substantial resolution' of clinical signs and/or at least 'moderately improved' in the general change in the lesion</measure>
    <time_frame>end of week 4</time_frame>
    <description>'Substantial resolution' is defined as a clinical score for thickness and scaliness of 0 and a clinical score for redness of 1 or less in the severity of clinical signs of the lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the sum of the scores (total sign score) for the severity of the three clinical signs (thickness, scaliness, redness) from baseline for each target lesion.</measure>
    <time_frame>end of week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO 80185 gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dovobet ® ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 80185 gel</intervention_name>
    <description>calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions</description>
    <arm_group_label>LEO 80185 gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dovobet ® ointment</intervention_name>
    <description>calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions</description>
    <arm_group_label>Dovobet ® ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Informed consent has been obtained.

          -  2. Japanese subjects

          -  3. Aged 20 years or above

          -  4. Clinical diagnosis of psoriasis vulgaris amenable to topical treatment of less than
             or equal to 30% BSA

          -  5. A target psoriasis lesion on the scalp and on the non-scalp area of the body, each
             lesion of a minimum size of 10 cm2 and scoring at least 2 (mild) for each of the
             clinical signs (redness, thickness and scaliness).

          -  6. Females of childbearing potential must have a negative result for a urine pregnancy
             test at Day 1 (Visit 1) and must agree to use an adequate method of birth control.

          -  7. Able to communicate with the (sub)investigator and understand and comply with the
             requirements of the trial.

        Exclusion Criteria:

          -  1. Systemic use of biological treatments with a potential effect on psoriasis vulgaris

          -  2. Systemic treatments with all therapies other than biological treatments with a
             potential effect on psoriasis vulgaris

          -  3. PUVA therapy, UVB therapy or UVA therapy

          -  4. Topical treatment of psoriasis on the areas to be treated with trial medication

          -  5. Topical treatment of psoriasis on the face, genitals or skin folds with vitamin D
             analogues, potent or very potent corticosteroids or immunosuppressants

          -  6. Topical treatment of conditions other than psoriasis with vitamin D analogues,
             potent or very potent corticosteroids or immunosuppressants

          -  7. Planned initiation of, or changes in, concomitant medication that may affect
             psoriasis vulgaris

          -  8. Patients with any of the following disorders (a) or symptoms (b) present on the
             areas to be treated with trial medication: (a) viral (e.g., herpes or varicella)
             lesions of the skin, fungal, spirochetal or bacterial skin infections, parasitic
             infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, acne
             vulgaris, atrophic skin, striae atrophicae, ichthyosis, acne rosacea, ulcers, burns,
             frostbite, wounds, animal skin disease (scabies, crabs, lice, etc.) or (b) fragility
             of skin veins.

          -  9. Other inflammatory skin diseases that may confound the evaluation of psoriasis
             vulgaris.

          -  10. Erythrodermic, exfoliative or pustular psoriasis

          -  11. Planned excessive exposure of areas to be treated with trial medication to either
             natural or artificial sunlight

          -  12. Known or suspected disorders of calcium metabolism associated with hypercalcaemia,
             or albumin-corrected serum calcium above the reference range

          -  13. Known or suspected severe renal insufficiency, severe hepatic disorders or severe
             heart disease.

          -  14. Known or suspected hypersensitivity to any components of the investigational
             products.

          -  15. Clinical signs or symptoms of Cushing's disease or Addison's disease

          -  16. Treatment with any non-marketed drug substance

          -  17. Current participation in any other interventional clinical trial

          -  18. Previously randomised in this trial

          -  19. Females who are pregnant, wishing to become pregnant or are breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hidemi Nakagawa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Corporation Bikyukai Kokubu Dermatology</name>
      <address>
        <city>Kitami-shi</city>
        <state>Hokkaido</state>
        <zip>090-0832</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>January 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LEO 80185 gel, calcipotriol, betamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 23, 2017</submitted>
    <returned>November 9, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

